Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Yong Peng,
†These authors have contributed equally to this work and share first authorship
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, there was an error. “Nanchang” is the wrong spelling. The correct spelling should be “Nanchong.”
This correction has been applied to the Abstract, the Methodology under the External Validation section, and to the first line of
Clinical information on patients aged ≥50 years with advanced pancreatic ductal adenocarcinoma.
| Variable | Whole population | Training population | Validation population | P | Nanchong Central Hospital | |||
|---|---|---|---|---|---|---|---|---|
| Number | % | Number | % | Number | % | 149 | ||
| 17,621 | 12,333 | 5,288 | ||||||
| Age | ||||||||
| 50-65 | 6,262 | 35.54% | 4,400 | 35.68% | 1,862 | 35.21% | 0.83 | 23 |
| 65-80 | 8,585 | 48.72% | 5,983 | 48.51% | 2,602 | 49.21% | 84 | |
| 80 | 2,774 | 15.74% | 1,950 | 15.81% | 824 | 15.58% | 42 | |
| Race | ||||||||
| Black | 2,072 | 11.76% | 1,472 | 11.94% | 600 | 11.35% | 0.91 | 0 |
| White | 14,135 | 80.22% | 9,861 | 79.96% | 4,274 | 80.82% | 0 | |
| Other | 1,414 | 8.02% | 1,000 | 8.11% | 414 | 7.83% | 149 | |
| Sex | ||||||||
| F | 8,437 | 47.88% | 5,919 | 47.99% | 2,518 | 47.62% | 0.56 | 64 |
| M | 9,184 | 52.12% | 6,414 | 52.01% | 2,770 | 52.38% | 85 | |
| AJCC Stages | ||||||||
| III | 3,087 | 17.52% | 2,172 | 17.61% | 915 | 17.30% | 0.47 | 43 |
| IV | 14,534 | 82.48% | 10,161 | 82.39% | 4,373 | 82.70% | 106 | |
| Site | ||||||||
| Head | 8,045 | 45.66% | 5,632 | 45.67% | 2,413 | 45.63% | 59 | |
| Body | 3,542 | 20.10% | 2,500 | 20.27% | 1,042 | 19.70% | 0.28 | 18 |
| Tail | 3,605 | 20.46% | 2,512 | 20.37% | 1,093 | 20.67% | 32 | |
| Others | 2,429 | 13.78% | 1,689 | 13.69% | 740 | 13.99% | 40 | |
| Grade a | ||||||||
| Well | 1,606 | 9.11% | 1,136 | 9.21% | 470 | 8.89% | 0.15 | 17 |
| Bad | 1,805 | 10.24% | 1,286 | 10.43% | 519 | 9.81% | 23 | |
| Unknow | 14,210 | 80.64% | 9,911 | 80.36% | 4,299 | 81.30% | 109 | |
| CA19-9 | ||||||||
| Positive | 5,371 | 30.48% | 3,734 | 30.28% | 1,637 | 30,96% | 0.63 | 53 |
| Negative | 12,250 | 69.52% | 8,599 | 69.72% | 3,651 | 69.04% | 96 | |
| Number | 0.38 | |||||||
| 1 | 14,333 | 81.34% | 10,043 | 81.43% | 4,290 | 81.13% | 105 | |
| >1 | 3,288 | 18.66% | 2,290 | 18.57% | 998 | 18.87% | 44 | |
| Radiation | 0.29 | |||||||
| Yes | 1,789 | 10.15% | 1,285 | 10.42% | 504 | 9.53% | 34 | |
| No | 15,832 | 89.85% | 11,048 | 89.58% | 4,784 | 90.47% | 115 | |
| Chemotherapy | ||||||||
| Yes | 10,784 | 61.20% | 7,493 | 60.76% | 3,291 | 62.24% | 0.36 | 97 |
| No | 6,837 | 38.80% | 4,840 | 39.24% | 1,997 | 37.76% | 52 | |
Well: Grades I and II; Bad: Grades III and IV.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.